<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; specific</title>
	<atom:link href="http://www.tapanray.in/tag/specific/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Aptness Of Pharma Marketing Audit In Covid Days And Beyond</title>
		<link>http://www.tapanray.in/aptness-of-pharma-marketing-audit-in-covid-days-and-beyond/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=aptness-of-pharma-marketing-audit-in-covid-days-and-beyond</link>
		<comments>http://www.tapanray.in/aptness-of-pharma-marketing-audit-in-covid-days-and-beyond/#comments</comments>
		<pubDate>Mon, 21 Sep 2020 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Aptness]]></category>
		<category><![CDATA[audit]]></category>
		<category><![CDATA[company-specific]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[Covid-10]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[dovetail]]></category>
		<category><![CDATA[findings]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[importance]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry-specific]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Marketing Audit]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[periodically]]></category>
		<category><![CDATA[Pilman]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[specific]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[Survey]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trends]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10266</guid>
		<description><![CDATA[That, Covid-19 pandemic has changed the operational dynamics of many areas of the pharma industry, as compared to the old normal, is being felt by many. These changes generally fall into two categories. Some are broad industry specific changes, giving &#8230; <a href="http://www.tapanray.in/aptness-of-pharma-marketing-audit-in-covid-days-and-beyond/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/aptness-of-pharma-marketing-audit-in-covid-days-and-beyond/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Quality Imbroglio And ‘Culture of Bending Rules’ in India</title>
		<link>http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-quality-imbroglio-and-culture-of-bending-rules-in-india</link>
		<comments>http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/#comments</comments>
		<pubDate>Mon, 27 May 2019 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bending]]></category>
		<category><![CDATA[bias]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[culpable]]></category>
		<category><![CDATA[culture]]></category>
		<category><![CDATA[Culture of Bending Rules]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[dubious]]></category>
		<category><![CDATA[Facts]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[letter]]></category>
		<category><![CDATA[margin]]></category>
		<category><![CDATA[multinational]]></category>
		<category><![CDATA[negative]]></category>
		<category><![CDATA[non-branded]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[quagmire]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[questionable]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[rules]]></category>
		<category><![CDATA[specific]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[US-FDA]]></category>
		<category><![CDATA[warning]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9539</guid>
		<description><![CDATA[“Bottle Of Lies Exposes The Dark Side Of The Generic-Drug Boom” &#8211; re-emphasized the book, released in May 2019.  This confirms, the raging debate on the questionable quality of many generic drugs manufactured in India and involving several top domestic pharma companies, &#8230; <a href="http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Should Pharma-Doctor Communication Be Also Gender-Specific?</title>
		<link>http://www.tapanray.in/should-pharma-doctor-communication-be-also-gender-specific/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=should-pharma-doctor-communication-be-also-gender-specific</link>
		<comments>http://www.tapanray.in/should-pharma-doctor-communication-be-also-gender-specific/#comments</comments>
		<pubDate>Mon, 26 Nov 2018 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[better]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[choosing]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[concordance]]></category>
		<category><![CDATA[content]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[female]]></category>
		<category><![CDATA[Gender]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[internists]]></category>
		<category><![CDATA[male]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[mortality]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[specific]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9268</guid>
		<description><![CDATA[Regardless of situations, while selecting a suitable doctor for patients, or for that matter, pharma companies engage with them for commercial reasons, their gender doesn’t matter much to many. What one generally looks for is, whether they are General Practitioners &#8230; <a href="http://www.tapanray.in/should-pharma-doctor-communication-be-also-gender-specific/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/should-pharma-doctor-communication-be-also-gender-specific/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
